The United States Food and Drug Administration (FDA) has received a new drug application (NDA) from Luye Pharma Group, an international pharmaceutical company, for its LY03005, a new chemical drug intended for the treatment of major depressive disorder, it was reported yesterday.
The product is also the second US FDA NDA involving the central nervous system (CNS) that the company has filed.
The application was based on the arrangement reached with the FDA under End-Of-Phase 2-CMC (EOP2-CMC) meeting and Pre-NDA (PNDA) meeting. LY03005 is an exclusive CNS product developed under the company's new chemical/therapeutic entities R&D platform. It is a serotonin-norepinephrine-dopamine triple reuptake inhibitor, and one of the active metabolites is a serotonin-norepinephrine reuptake inhibitor.
Luye Pharma has obtained patents covering the chemical compound, crystal form and formulation of LY03005.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference